IL7 and neoplasm: 85% of mice in the 16-21/7 group stayed tumor-free, while only 40% and 20% of mice in the 16–21 group and the 16-7 group were immune to lethal tumor challenge (Fig. 2C–E), which suggested a synergy between IL-21 and IL-7 when co-expressed in whole-cell vaccines.